This page brings together the European Medicines Agency's (EMA) latest information on cancer. It lists:
Rybrevant is a cancer medicine used to treat adults with advanced non-small cell lung cancer (NSCLC) whose cancer cells have certain genetic changes. These changes are in the gene for a protein that...
Ceplene is a medicine used in combination with interleukin-2 (a cancer medicine) as maintenance treatment in adults with acute myeloid leukaemia (AML), a type of cancer affecting the white blood...
Jylamvo is an anti-inflammatory and cancer medicine used to treat the following conditions: active rheumatoid arthritis (a disease causing inflammation in joints) in adults; severe juvenile...
Tecartus is a cancer medicine used to treat: adults with mantle cell lymphoma (a cancer of B cells, a type of white blood cell) when the cancer has come back after two or more previous treatments,...
This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its...
Five new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended five medicines for approval at its December 2022 meeting. The CHMP recommended granting a conditional marketing authorisation for the advanced therapy...
EMA has recommended a conditional marketing authorisation in the European Union (EU) for Tecvayli (teclistamab) for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies,...
EMA’s human medicines committee, CHMP, has recommended that Rubraca (rucaparib camsylate) should no longer be used as third-line treatment for cancers of the ovary, fallopian tubes or peritoneum with a BRCA mutation in patients whose cancer has come...
Nine new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended nine medicines for approval at its June 2022 meeting. The CHMP recommended granting a marketing authorisation for COVID-19 Vaccine (inactivated,...
Nine new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended nine medicines for approval at its May 2022 meeting. A recommendation for marketing authorisation was adopted for Cevenfacta (eptacog beta (activated))...
Four new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended four medicines for approval in the European Union (EU) at its April 2022 meeting. The CHMP gave a positive opinion for Filsuvez * (birch bark extract) for...
The third Cancer Medicines Forum took place on the 20th December 2022 and looked at challenges...
The EMA's Cancer Medicines Forum (CMF) aims to explore how EMA can contribute towards addressing...
This first meeting of EMA's Cancer Medicines Forum looked at challenges around research into...
The European Medicines Agency is hosting a symposium to explore themes such as the natural...